Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Put Hughes Syndrome on Your Radar

Graham R.V. Hughes, MD  |  Issue: April 2007  |  April 1, 2007

There are two “new” diseases of the late 20th century—AIDS and the antiphospholipid syndrome.
—Miguel Villardel, MD, professor of medicine, Hospital Valle de Hebron, Barcelona

Since its clinical description in 1983, antiphospholipid syndrome (APS or Hughes Syndrome) has become the domain not only of rheumatologists and obstetricians, but of neurologists, cardiologists, psychiatrists, otolaryngologists, and orthopedists. Like lupus, APS embraces all clinical specialities.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Brief History of APS

In 1983, my colleagues and I described in detail a syndrome involving—uniquely—both arterial and venous thrombosis, and including prominent neurological features, including strokes, seizures, memory loss, and chorea. In addition, this syndrome was associated with occasional thrombocytopenia, livedo reticularis, labile hypertension, recurrent miscarriage, and internal organ thrombosis such as Budd-Chiari syndrome.1,2 We recognized that the syndrome was “sufficiently different from typical systemic lupus to warrant separate consideration”—originally calling it the anticardiolipin syndrome.2 Led by the late Aziz Gharavi, MD, and E. Nigel Harris, MPhil, MD, DM, we set up sensitive immunoassays for antiphospholipid antibodies (aPL), changed the name to APS, and introduced the term primary APS for stand-alone cases.2,3

The worldwide interest in this syndrome has led to its recognition in a wide variety of clinical states increasing diagnosis. Indeed, it seems a fairly safe prediction that APS will overtake lupus in prevalence. A rough one-in-five rule seems to apply for the contribution of APS to various clinical conditions—one in five cases of recurrent miscarriage, one in five strokes in people under 45, one in five cases of deep vein thrombosis (DVT). Eventually, this estimate may also pertain to other major illnesses including myocardial infarction in the young, idiopathic teenage epilepsy, and possibly even migraine.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pathogenesis and Clinical Features

APS is an autoimmune disease in which antibodies directed against phospholipid-protein complexes appear to lead directly to thrombosis. Like all autoimmune diseases APS has a genetic component, and cases of thyroid disease, Sjögren’s syndrome, and lupus are frequently seen in families with APS.

While arterial and venous thromboses are the hallmarks of the syndrome, there are other clinical clues. Headache—particularly migraine—is often an early feature going back to childhood, and often familial. Livedo reticularis is an important physical sign, and a dry Shirmer’s test, suggesting underlying Sjögren’s syndrome, is a clue to the disease’s autoimmune pedigree. Table 1 lists some of the major differences between APS and other pro-thrombotic disorders.

Clinical Pointers in the Differential Diagnosis of APS
click for large version
Table 1: Clinical Pointers in the Differential Diagnosis of APS

Neurological Considerations

Stroke: The most feared complication of APS is stroke, with up to 20% of strokes in people under 45 possibly having this etiology. In this setting, the MRI can be misleading (e.g., false negatives) and we look forward to the development of more sensitive and available screening techniques. Estimates for the frequency of stroke in patients with APS vary widely, and some studies have been hampered by methodological problems.4

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Antiphospholipid Antibody Syndrome (APS)AutoimmuneHughes SyndromePathogenesisTreatment

Related Articles

    APS: What Rheumatologists Should Know about Hughes Syndrome

    February 17, 2016

    The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…

    Antiphospholipid Antibody Testing Update

    January 13, 2012

    Successes, challenges, and controversies of diagnostic methods for APS

    Why Antiphospholipid Antibody Syndrome Should Be On Your Radar

    February 1, 2014

    With a wide range of clinical manifestations and frequent occurrence among rheumatology patients, APS is one for rheumatologists to watch

    Case Report: A Patient Presents with Digital Ischemia & Gangrene

    June 10, 2023

    Defined by the presence of antiphospholipid antibodies (aPL) in individuals with clinical evidence of thrombosis or pregnancy morbidity, antiphospholipid syndrome (APS) is a systemic autoimmune thrombophilia. Clinical thrombosis, which should be confirmed by objective validated criteria (e.g., imaging studies or histopathology), can occur in the arterial, venous or small vessel vasculature and is not limited…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences